NVS: Novartis announces Phase III remibrutinib results showing comprehensive disease control and robust safety

What happened

Novartis published a press release (Oct. 23, 2026) reporting Phase III results for remibrutinib in RMS, saying the drug delivered comprehensive disease control and demonstrated a robust safety profile. The company describes the findings as statistically significant and clinically meaningful; the release is available at the Novartis website (linked in the news digest).

Sources: S1

Why it matters

Positive Phase III efficacy and a favorable safety readout are the key clinical milestones that support potential regulatory filing and commercialization discussions. For traders, this is a company‑level clinical catalyst: the issuer release contains the definitive numeric endpoints, statistical details, patient population and any stated regulatory plans — review those items before sizing exposure.

Sources: S1

What remains uncertain

• market data contains the issuer press release headline and summary but not the full numeric endpoints, p‑values, subgroup results or Novartis’ stated regulatory timeline — see the company release for those details.
• The digest confirms the Phase III result as reported by Novartis; independent peer‑reviewed publication or regulatory filings are not included in the supplied market data.